KRTX Karuna Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRTX

Price (delayed)

$169.09

Market cap

$6.37B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.15

Enterprise value

$6.12B

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and ...

Highlights
The company's quick ratio has surged by 115% YoY but it fell by 36% QoQ
The debt has surged by 146% year-on-year
The company's revenue has shrunk by 86% YoY and by 47% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://karunatx.com
Peers: OMGA

Key stats

What are the main financial stats of KRTX
Market
Shares outstanding
37.67M
Market cap
$6.37B
Enterprise value
$6.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.46
Price to sales (P/S)
1,055.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,018.04
Earnings
Revenue
$6.01M
EBIT
-$353.02M
EBITDA
-$351.63M
Free cash flow
-$305.42M
Per share
EPS
-$10.15
Free cash flow per share
-$8.14
Book value per share
$37.91
Revenue per share
$0.16
TBVPS
$39.23
Balance sheet
Total assets
$1.47B
Total liabilities
$52.54M
Debt
$15.81M
Equity
$1.42B
Working capital
$1.41B
Liquidity
Debt to equity
0.01
Current ratio
37.61
Quick ratio
37.21
Net debt/EBITDA
0.7
Margins
EBITDA margin
-5,847.8%
Gross margin
100%
Net margin
-5,885.8%
Operating margin
-6,569.2%
Efficiency
Return on assets
-26.3%
Return on equity
-27.1%
Return on invested capital
-39.6%
Return on capital employed
-24.6%
Return on sales
-5,871%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRTX stock price

How has the Karuna Therapeutics stock price performed over time
Intraday
-0.68%
1 week
1.84%
1 month
-5.81%
1 year
-24.68%
YTD
-13.95%
QTD
-22.02%

Financial performance

How have Karuna Therapeutics's revenue and profit performed over time
Revenue
$6.01M
Gross profit
$6.01M
Operating income
-$395M
Net income
-$353.91M
Gross margin
100%
Net margin
-5,885.8%
KRTX's operating margin has plunged by 118% from the previous quarter
The net margin has dropped by 111% since the previous quarter
The operating income has dropped by 95% year-on-year and by 16% since the previous quarter
The company's revenue has shrunk by 86% YoY and by 47% QoQ

Growth

What is Karuna Therapeutics's growth rate over time

Valuation

What is Karuna Therapeutics stock price valuation
P/E
N/A
P/B
4.46
P/S
1,055.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,018.04
KRTX's EPS is down by 50% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 28% less than the 5-year quarterly average of 6.2 and 17% less than the last 4 quarters average of 5.4
The equity has declined by 4.6% since the previous quarter
The company's revenue has shrunk by 86% YoY and by 47% QoQ
The price to sales (P/S) is 58% more than the last 4 quarters average of 667.3

Efficiency

How efficient is Karuna Therapeutics business performance
KRTX's return on sales has dropped by 111% since the previous quarter
Karuna Therapeutics's ROIC has increased by 43% YoY and by 16% from the previous quarter
Karuna Therapeutics's return on equity has increased by 37% YoY and by 10% QoQ
The return on assets is up by 36% year-on-year and by 10% since the previous quarter

Dividends

What is KRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRTX.

Financial health

How did Karuna Therapeutics financials performed over time
The company's quick ratio has surged by 115% YoY but it fell by 36% QoQ
Karuna Therapeutics's current ratio has surged by 112% YoY but it has decreased by 37% QoQ
The debt is 99% smaller than the equity
The debt has surged by 146% year-on-year
The debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.